DMT / 5-MeO-DMT

Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms. When ingested, it converts to psilocin, which activates serotonin receptors in the brain, particularly the 5-HT2A receptor. This leads to altered perception, enhanced emotional processing, and increased neuroplasticity. Research shows psilocybin creates rapid and durable antidepressant effects, with single doses producing symptom reductions lasting weeks to months. Compass Pathways' COMP360, a synthetic psilocybin formulation, successfully met primary endpoints in two Phase 3 trials for treatment-resistant depression in 2026, showing a 3.8-point MADRS reduction compared to control doses. The compound appears to work by disrupting rigid thought patterns and promoting cognitive flexibility, while simultaneously reducing activity in the brain's default mode network, which is often hyperactive in depression. Johns Hopkins, Imperial College London, and other leading institutions have published groundbreaking studies demonstrating psilocybin's efficacy for depression, anxiety in cancer patients, addiction, and obsessive-compulsive disorder. The therapeutic effects appear enhanced when combined with psychotherapy and intention-setting.

LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first synthesized by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors, producing profound alterations in consciousness, perception, mood, and cognition lasting 8-12 hours. During the 1950s-60s, LSD showed remarkable promise in psychiatric research for treating alcoholism, anxiety, and enhancing psychotherapy before political backlash led to prohibition. Modern neuroscience reveals LSD increases brain network connectivity, particularly between regions that don't normally communicate, promoting cognitive flexibility and creative problem-solving. Unlike psilocybin, LSD has a longer duration and tends toward more geometric and abstract visual experiences. Recent clinical trials on LSD microdosing (10-20 μg doses, sub-perceptual) show it is safe in outpatient settings but lacks proven efficacy beyond placebo for core ADHD symptoms in a 2025 phase 2A trial. However, ongoing research explores LSD's potential for anxiety, depression, and cluster headaches. The compound's ability to induce ego dissolution and mystical experiences correlates with therapeutic benefits. Imperial College London pioneered modern LSD neuroimaging, revealing how it temporarily dissolves the brain's default mode network, allowing for psychological flexibility and new perspectives on entrenched problems.